Antiretroviral therapy (ART) effectively manages HIV by suppressing viral replication. It's crucial for healthcare professionals (HCPs) to keep abreast of ART updates for optimal patient care. Dr. Eric Daar, Harbor-UCLA Medical Center, reports on CROI 2024, underscoring the efficacy of long-acting injectable (LAI) therapies in trials like CARES, MOCHA, and LATITUDE. The findings support LAI therapy's potential for global HIV treatment programs, including in resource-limited settings like sub-Saharan Africa.
The treatment of people with HIV (PWH)/hepatitis B virus (HBV) co-infection, especially those who have additional comorbidities requiring multiple drug therapies can be problematic. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a co-formulated medication consisting of two components ...
HIV is a significant global health issue for which there is no cure. However, the availability of antiretroviral therapy (ART) has made it possible to effectively treat and prevent HIV infection, leading to a considerable decrease in associated deaths and ...
Heavily treatment-experienced people living with HIV (HTE-PLWH) represent a minority of those living with HIV.1Â While there is variability in the definitions of HTE-PLWH, its prevalence is estimated to be between 1 and 10% of the total number of people living with ...
The Russian invasion of Ukraine represents the largest humanitarian crisis that Europe has faced in decades. In the first 4 months of the war, over 9.9 million refugees crossed the Ukrainian border, and over 6.1 million Ukrainian refugees were registered across Europe.1Â Before ...
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for ...
An alliance of United Nations organizations and associated partners have unified to create the United Nations Programme on HIV/AIDS (UNAIDS), which has set a goal of ending the HIV epidemic by the year 2030.1 Similarly, the ‘Ending the HIV Epidemic ...
Welcome to the first issue of touchREVIEWS in Infectious Diseases, which aims to publish topical interviews, reviews, editorials, case studies and original research in the field of infectious diseases. The development of antibiotics and vaccines remain among the greatest accomplishments ...
The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs ...
HIV/HBV co-infection increases the morbidity and mortality beyond those caused by either infection alone and there are number of challenges in it's treatment. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins touchINFECTIOUS DISEASES to discuss ...
As a result of prolonged virologic suppression, improved clinical outcomes and longer survival, patients with HIV are exposed to anti-retroviral agents for decades. Despite advances in anti-retroviral therapy, many people living with HIV and taking long-term anti-retroviral therapy have a ...
We had the pleasure to meet with Christoph Spinner (University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany) to discuss the DISCOVER open label phase results. The abstract entitled: ‘Outcomes of participants switching from F/TDF to ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.